Skip to content
Aminoscope
Head-to-head

Pemvidutide vs Tirzepatide

An approved GIP/GLP-1 with the largest weight-loss figure in the class against an investigational GLP-1/glucagon agonist competing on what the lost weight is made of.

By Julian RothResearch & dataUpdated October 2026

Short answer

The clearest difference is regulatory. Tirzepatide is FDA-approved, and pemvidutide is still investigational in the US. Tirzepatide is the one to look at if FDA approval matters to you, while pemvidutide is marketed for weight loss and MASLD/MASH. On the evidence, pemvidutide has human clinical data and tirzepatide has approval-level evidence.

Pemvidutide

Clinical data

A GLP-1/glucagon dual agonist aimed specifically at preserving lean mass while cutting liver fat; real Phase 2 MASLD data, but Phase 3 has not started and it remains fully investigational.

Full Pemvidutide evidence review

Tirzepatide

Zepbound / Mounjaro

FDA-approved

Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.

Full Tirzepatide evidence review

Pemvidutide vs Tirzepatide: head to head

FDA status / approved use

Pemvidutide

Investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 planned

Tirzepatide

Prescription drug sold as Mounjaro and Zepbound
Marketed for

Pemvidutide

Weight loss, MASLD/MASH

Tirzepatide

Weight loss, type-2 diabetes
Outcome areas

Pemvidutide

Weight loss / appetite; Liver / detox; Muscle / strength / lean mass

Tirzepatide

Weight loss / appetite; Blood sugar / insulin sensitivity
Evidence grade

Pemvidutide

Clinical data

Tirzepatide

FDA-approved
How it works

Pemvidutide

Dual GLP-1 and glucagon receptor agonist; glucagon arm stimulates liver fat oxidation

Tirzepatide

Dual agonist of the GLP-1 and GIP receptors
Route and dosing

Pemvidutide

Once-weekly injection

Tirzepatide

Subcutaneous, once weekly (Zepbound label); maintenance 5, 10 or 15 mg once weekly (10 or 15 mg for sleep apnea)
Headline human result

Pemvidutide

About −15.6% mean weight loss at 2.4 mg vs −2.2% on placebo over 48 weeks in the Phase 2 MOMENTUM trial (391 adults)

Tirzepatide

20.9% mean weight loss vs 3.1% on placebo at 72 weeks (SURMOUNT-1, 15 mg weekly)
Strongest evidence

Pemvidutide

Phase 2 MASLD RCT, 2025Pemvidutide evidence reviewPubMed 41237796

Tirzepatide

SURMOUNT-1, NEJM 2022Tirzepatide evidence reviewPubMed 35658024
Key safety signal

Pemvidutide

No long-term safety data; glucagon action needs long-term cardiometabolic monitoring

Tirzepatide

Gastrointestinal side effects, the same class as semaglutide
How it is obtained

Pemvidutide

Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals

Tirzepatide

Prescription. Manufacturer self-pay for Zepbound runs $299–$449 per fill, against a $1,086 list priceZepbound cost breakdown

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Tirzepatide is approved and pemvidutide is Phase 2, which decides the practical question outright. On magnitude tirzepatide also leads — about 21% in SURMOUNT-1 against roughly −15.6% in the 48-week MOMENTUM trial — though those are separate trials in different populations and not a head-to-head. Pemvidutide’s argument is deliberately not the headline number: Altimmune reports about 74.5% of the weight lost was fat and 25.5% lean, and frames the glucagon arm as protecting body composition. That is best read as the hypothesis the program is built around rather than a demonstrated advantage, for two reasons — it is a company-reported ratio from a Phase 2, and lean mass on a scan is not the same thing as function preserved. Pemvidutide does carry Phase 2b MASH data, an indication tirzepatide is not approved for.

Pemvidutide fits if

You are interested in the body-composition and liver-disease angle specifically, and are following a drug years away from any approval decision.

Tirzepatide fits if

You want the approved drug with the largest weight-loss effect and a real prescribing pathway.

Pemvidutide vs Tirzepatide: common questions

Is tirzepatide FDA-approved but pemvidutide not?
Yes. Tirzepatide is a prescription drug sold as Mounjaro and Zepbound. Pemvidutide is investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 planned.
Which has stronger human evidence, pemvidutide or tirzepatide?
Tirzepatide. It has approval-level evidence (key source: SURMOUNT-1, NEJM 2022), while pemvidutide has human clinical data (key source: Phase 2 MASLD RCT, 2025).
What are the main safety concerns with pemvidutide and tirzepatide?
Pemvidutide has no long-term safety data; glucagon action needs long-term cardiometabolic monitoring. For tirzepatide, watch for gastrointestinal side effects, the same class as semaglutide.

Key studies behind each

Pemvidutide

  1. Harrison SA, Browne SK, Suschak JJ, et al. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. PubMed 39002641
  2. Noureddin M, Harrison SA, Loomba R, et al. (2025). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. PubMed 41237796

Tirzepatide

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024
  3. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PubMed 34170647
  4. Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PubMed 40353578

The full evidence reviews

Related comparisons